# Attention and/or concern variants for COVID-19 genomic sequencing in Brazil

## Variantes de atenção e/ou preocupação por sequenciamento genômico do COVID-19 no Brasil

### Variantes de atención y / o preocupación para la secuenciación genómica de COVID-19 no Brasil

Linconl Agudo Oliveira Benito¹, Rosana da Cruz Lima², Margô Gomes de Oliveira Karnikowski³, Izabel Cristina Rodrigues da Silva⁴, Helder Lima Garcia Azevedo⁵

**How to cite:** Benito LAO, Lima RC, Karnikowski MGO, Silva ICR, Azevedo, HLG. Attention and/or concern variants for COVID-19 genomic sequencing in Brazil. REVISA. 2021;10(Esp2): 783-7. Doi: <a href="https://doi.org/10.36239/revisa.v10.n2.p783a787">https://doi.org/10.36239/revisa.v10.n2.p783a787</a>



ISSN Online: 2179-0981

In the city of Wuhan, Hubei province in the People's Republic of China, an event classified as an outbreak was registered by the local authorities, which allowed the diagnosis of pneumonia (PNM) to be carried out.<sup>1,2</sup> This important phenomenon was dated to the month of December of the year 2019, being identified a strain of coronavirus unknown until that time, and which spread rapidly, showing its high potential for transmissibility in twenty-four (24) other countries.<sup>1-3</sup>

In this context, this fact was notified on January 7, 2020, as a new strain belonging to the coronavirus, which was not recognized in humans to date.<sup>3-5</sup> As of January 30, 2020, the Organization World Health Organization (WHO), defended that this outbreak was constituted as a noisy public health problem, constituting also as a true Public Health Emergency of International Importance (PHEII).<sup>4-5</sup>

On February 11, 2020, it was given the designation of SARS-CoV-2, as it was responsible for causing the disease that became known as COVID-19,<sup>4,5,6</sup> On February 26, 2020, the first notification of a confirmed case in Brazil by the Ministry of Health (MH) of COVID-19 and, on March 11 of the same year, the WHO characterized COVID-19 as a pandemic, communicating to all nations updated information on its complexity and magnitude of this new phenomenon.<sup>6,7,8</sup>

According to the MS, the most identified classes of coronaviruses to date are the "alpha coronavirus HCoV-229E", the "alpha coronavirus HCoV-NL63", the "beta coronavirus HCoV-OC43", the "beta coronavirus HCoV-HKU1", "SARS-CoV", which has been identified as the cause of severe acute respiratory syndrome (SARS), "MERS-CoV", which has been identified as the cause of Middle East respiratory syndrome (MERS) and also SARSCoV-2.9 Regarding the different types of classification of the aforementioned variants of COVID-19, the WHO took the initiative of bringing together an association of experts, which instituted the nomenclatures to be used to designate what is understood as "Variants of Interest" (VOI) and the "Variants of Concern" (VOC), using letters of the Greek alphabet for this action, such as alpha ( $\alpha$ ), beta ( $\beta$ ), delta ( $\alpha$ ) or  $\alpha$ ), gamma ( $\alpha$ ) and omicron (O or o). 10,-11

With regard to SARS-CoV-2 VOCs, they receive this designation, as they have the possibility of increased frequency in their virulence, changes in their clinical presentation, increased transmissibility or harmful alteration of COVID-19, or even in the reduction of its effectiveness in social and diagnostic measures, public health or accessible therapies. <sup>10,11</sup> The VOI, on the other hand, have this designation because it caused community transmission of multiple cases of COVID-19, and also, of its genome having undergone mutations that changed its viral phenotype, in addition to needing to be detected in several nations. <sup>10,11</sup>

Another important issue that characterizes VOI is that it can be classified by carrying out an assessment by the Working Group on the Evolution of the SARS-CoV-2 Virus or otherwise by the WHO.<sup>10,11</sup> In table 1, COVID-19's VOCs of concern are presented in relation to the labels instituted by WHO, strains, GISAID clade/strain, first documented samples and respective designation dates.

WHO	Lineage	GISAID	GISAID First document	
Label	C	Clado/lineage	samples	date
Alpha	B.1.1.7	GRY(antigamente	Reino Unido,	18/12/2020
		GR/501Y.V1)	september/ 2020	
Beta	B.1.351	GH/501Y.V2	África do Sul,	18/12/2020
			may/2020	
Gamma	P.1	GR/501Y.V3	Brasil,	11/01/2021
			november/2020	
Delta	B.1.617.2	G/452R.V3	Índia,	VOI: 04/04/2021
			october/2020	VOC:11/05/2021

**Source:** Adapted from WHO, 2021.

In Table 1, the frequencies of confirmed and notified cases of the variants, federative units (UF) in Brazil, between epidemiological weeks (EW) 2 to 47, up to November 2021, are presented, totaling a universe of 44,334 cases with mean and standard deviation ( $1.642\pm2.916,3$ ).

<sup>\*</sup> The data presented here were updated on 12/01/2021.

<sup>\*\*</sup> Due to the potential complexity of COVID-19 and its variants, the aforementioned data is updated daily.

<sup>\*\*\*</sup> The authors are faithful to the sources consulted...

Benito LAO, Lima RC, Karnikowski MGO, Silva ICR, Azevedo, HLG

**Table 1** – Frequency of confirmed and notified cases of attention and/or concern (VOC) variants by genomic sequencing, by FUs, in Brazil, between SE 2 to 47, in the year 2021 (n=44.334):\*,\*\*,\*\*\*

	Total	VOC Gama	VOC Delta	VOC Alfa	VOC Beta	VOC Ômicron
UF	f (%)	f (%)	f (%)	f (%)	f (%)	f (%)
SP	14.113 (31,8)	2.915 (12,7)	11.138 (53,4)	54 (12)	3 (60)	3 (100)
RJ	6.403 (14,4)	3.522 (15,3)	2.825 (13,5)	56 (12,4)	-	-
MG	5.057 (11,4)	3.019 (13,1)	1.831 (8,8)	207 (46)	-	-
GO	2.889 (6,5)	2.199 (9,6)	652 (3,1)	37 (8,2)	1 (20)	-
DF	2.147 (4,8)	1.026 (4,5)	1.113 (5,3)	8 (1,8)	-	-
AM	1.930 (4,4)	1.687 (7,3)	242 (1,2)	1 (0,2)	-	-
PE	1.683 (3,8)	1.304 (5,7)	376 (1,8)	3 (0,7)	-	-
CE	1.552 (3,5)	1.132 (4,9)	419 (2)	1 (0,2)	-	-
ES	1.131 (2,6)	429 (1,9)	684 (3,3)	18 (4)	-	-
SC	1.107 (2,5)	715 (3,1)	386 (1,8)	6 (1,3)	-	-
BA	933 (2,1)	566 (2,5)	326 (1,6)	40 (8,9)	1 (20)	-
RO	925 (2,1)	883 (3,8)	42 (0,2)	-	-	-
PR	917 (2,1)	618 (2,7)	288 (1,4)	11 (2,4)	-	-
RS	495 (1,1)	427 (1,9)	66 (0,3)	2 (0,4)	-	-
MS	480 (1,1)	379 (1,6)	101 (0,5)	-	-	-
PB	385 (0,9)	257 (1,1)	127 (0,6)	1 (0,2)	-	-
AL	361(0,8)	348 (1,5)	12 (0,1)	1 (0,2)	-	-
SE	324 (0,7)	294 (1,3)	29 (0,1)	1 (0,2)	-	-
PA	308 (0,7)	239 (1)	69 (0,3)	-	-	-
AC	250 (0,6)	231(1)	19 (0,1)	-	-	-
RR	236 (0,5)	234 (1)	2 (0,0)	-	-	-
MA	227 (0,5)	174 (0,8)	53 (0,3)	-	-	-
TO	163 (0,4)	137 (0,6)	26 (0,1)	-	-	-
RN	109 (0,2)	75 (0,3)	33 (0,2)	1 (0,2)	-	-
PI	103 (0,2)	103 (0,4)	-	-	-	-
MT	90 (0,2)	84 (0,4)	4 (0,0)	2 (0,4)	-	-
AP	16 (0,0)	11 (0,0)	5 (0,0)	-	-	-
Total	44.334 (100)	23.008 (100)	20.868 (100)	450 (100)	5 (100)	3 (100)

Source: Adapted from the State Departments of Health (SDH) and MS, 2021.

Among the SE 2 to 47 of the year 2021, it was found that the VOC Gamma registered the greatest preponderance with 51.9% (n=23,008), followed by VOC Delta with 47.1% (n= 20,868), VOC Alpha with 1% (n=450), VOC Beta with 5% (n=0.01) and VOC Ômicron 0.01% (n=03).12 The state of São Paulo (SP) registered the greatest preponderance among the FUs analyzed, adding 31.8% (n=14,113) and Amapá (AP) the smallest with 0.04% (n=16).<sup>12</sup>

<sup>\*</sup> The data presented here were last updated on the day 01/12/2021.

<sup>\*\*</sup> Due to the potential complexity of COVID-19 and its variants, the aforementioned data is updated daily.

<sup>\*\*\*</sup> The authors are faithful to the sources consulted.

What is noteworthy in this table is the presence of three (03) cases of VOC Ômicron identified in the state of SP in November 2021.

According to WHO, the first known Ômicron VOC infection (B.1.1.529) was from a sample collected on 9 November 2021, which was first reported to WHO South Africa on 24 November from 2021. 13-15

Thus, and according to some researchers, Ômicron VOC (B.1.1.529) comprises a high number of developed mutations, some of which are possibly classified as worrisome.<sup>13-15</sup> The complexity and magnitude of Ômicron VOC (B.1.1.529) is such that preliminary evidence suggests the presence of an increased risk of reinfection in people affected by it, when compared to other types of VOCs in COVID-19.<sup>13-15</sup>

#### Acknowledgment

This research did not receive funding for its completion.

#### References

- 1. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(9). doi: http://dx.doi.org/10.1038/s41368-020-0075-9.
- 2. Callaway E, Cyranoski D. Why snakes probably aren't spreading the new China virus. Nature. 2020. doi: http://doi.org/10.1038/d41586-020-00180-8.
- 3. Organização Pan-Americana da Saúde. Folha informativa sobre COVID-19. Histórico da pandemia de COVID-19. Disponível em: [https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19]. Acesso em: 01 nov 21.
- 4. Bonavia A, Zelus BD, Wentworth DE, Talbot PJ, Holmes KV. Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229E. Journal of Virology. 2003; 77(4); 2530-2538. doi: <a href="https://doi.org/10.1128/JVI.77.4.2530-2538.2003">https://doi.org/10.1128/JVI.77.4.2530-2538.2003</a>.
- 5. Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC. Improving the Evidence Base for Decision Making During a Pandemic: The Example of 2009 Influenza A/H1N1. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. 2011:9(2);89-115. doi: <a href="http://doi.org/10.1089/bsp.2011.0007">http://doi.org/10.1089/bsp.2011.0007</a>.
- 6. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 Influenza A(H1N1) Virus Illness Among Pregnant Women in the United States. *JAMA*. 2010;303(15):1517–1525. doi: http://doi.org/10.1001/jama.2010.479.
- 7. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico Especial. Doença pelo Novo Coronavírus COVID-19. Epidemiológica 40: 24/10 a 30/10/2021. Número 87. Brasília: MS, 2021. 109p. Disponível em: [https://www.gov.br/saude/pt-br/media/pdf/2021/novembro/06/boletim\_epidemiologico\_covid\_87\_5nov21\_-seg2.pdf]. Acesso em: 09 nov 21.
- 8. Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Critical Reviews in Clinical Laboratory Sciences. 2020;57(6):365-388. doi: <a href="http://doi.org/10.1080/10408363.2020.1783198">http://doi.org/10.1080/10408363.2020.1783198</a>
- 9. Brasil. Ministério da Saúde. Coronavírus: o que você precisa saber e como prevenir o contágio. Disponível em: [https://coronavirus.saude.gov.br/]. Acesso em: 20 jun 2020.
- 10. Organização Pan-Americana da Saúde. OMS anuncia nomenclaturas

- Benito LAO, Lima RC, Karnikowski MGO, Silva ICR, Azevedo, HLG simples e fáceis de pronunciar para variantes de interesse e de preocupação do SARS-CoV-2. Nomenclaturas de variantes do SARS-CoV-2 (atualização em 31 de maio). Disponível em: [ <a href="https://www.paho.org/pt/noticias/1-6-2021-oms-anuncia-nomenclaturas-simples-e-faceis-pronunciar-para-variantes-interesse-e">https://www.paho.org/pt/noticias/1-6-2021-oms-anuncia-nomenclaturas-simples-e-faceis-pronunciar-para-variantes-interesse-e</a>]. Acesso em: 11 nov 21.
- 11. World Health Organization. Home. Activities. Tracking SARS-CoV-2 variants. Available in: [ <a href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</a>]. Access on: 11 nov 21.
- 12. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico Especial. Doença pelo Novo Coronavírus COVID-19. Semana Epidemiológica 47 (21/11 a 27/11/2021). Número 91. Brasília: MS, 108p. disponível em: [https://www.gov.br/saude/pt-br/media/pdf/2021/dezembro/3/boletim\_epidemiologico\_covid\_91\_2dez21\_.pdf]. Acesso em: 06 dez 21.
- 13. World Health Organization. Home. News. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available in: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern]. Access in: 06 dez 21.
- 14. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear BMJ.2021;375:n2943 <a href="https://doi.org/10.1136/bmj.n2943">doi:10.1136/bmj.n2943</a>.
- 15. Tanne JH. Covid 19: Omicron is a cause for concern, not panic, says US president BMJ.2021;375:n2956 doi:10.1136/bmj.n2956.